ArticleOncotarget2018

Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study.

Taku Fujimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.